Breaking News, Trials & Filings

Ori Biotech’s IRO Platform Receives FDA AMT Designation

Provides developers using IRO with earlier and more frequent FDA engagement to help accelerate regulatory filings.

Ori Biotech, a cell and gene therapy (CGT) manufacturing technology company, has received Advanced Manufacturing Technology (AMT) designation from the U.S. FDA for the IRO platform. Launched in 2024, IRO is one of the first technologies to receive AMT designation, validating the platform as a next-generation solution to help overcome challenges in cell and gene therapy manufacturing. IRO is a fully closed system that automates, digitizes, and standardizes the most labor-intensive steps o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters